1. Table of Contents
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Chagas Disease (American Trypanosomiasis) Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Chagas Disease (American Trypanosomiasis) Clinical Trials by Region
2.2.2 Average Enrollment of Chagas Disease (American Trypanosomiasis) Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Chagas Disease (American Trypanosomiasis) Treatment, 2019

3. Region wise Chagas Disease (American Trypanosomiasis) Clinical Trials
3.1 Asia Pacific Chagas Disease (American Trypanosomiasis) Clinical Trials by Country
3.2 Europe Chagas Disease (American Trypanosomiasis) Clinical Trials by Country
3.3 North America Chagas Disease (American Trypanosomiasis) Clinical Trials by Country
3.4 Middle East and Africa Chagas Disease (American Trypanosomiasis) Clinical Trials by Country
3.5 South and Central America Chagas Disease (American Trypanosomiasis) Clinical Trials by Country

4. Chagas Disease (American Trypanosomiasis) Clinical Trial Trends
4.1 Start Year wise Chagas Disease (American Trypanosomiasis) Clinical Trials
4.2 Phase wise Chagas Disease (American Trypanosomiasis) Clinical Trials
4.3 Trial Status wise Chagas Disease (American Trypanosomiasis) Clinical Trials
4.4 Trial Type wise Chagas Disease (American Trypanosomiasis) Clinical Trials

5. Chagas Disease (American Trypanosomiasis) Average Enrollment Trends
5.1 Average Enrollment in Chagas Disease (American Trypanosomiasis) Trials by Year
5.2 Average Enrollment in Chagas Disease (American Trypanosomiasis) Trials by Phase
5.3 Average Enrollment in Chagas Disease (American Trypanosomiasis) Trials by Status
5.4 Average Enrollment in Chagas Disease (American Trypanosomiasis) Trials by Type of Trial

6. Companies Participating in Chagas Disease (American Trypanosomiasis) Clinical Trials
6.1 Chagas Disease (American Trypanosomiasis) Trials by Sponsor Type
6.2 Chagas Disease (American Trypanosomiasis) Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7 Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Chagas Disease (American Trypanosomiasis) Trials- Phase 1
7.2 Chagas Disease (American Trypanosomiasis) Trials- Phase 2
7.3 Chagas Disease (American Trypanosomiasis) Trials- Phase 3
7.4 Chagas Disease (American Trypanosomiasis) Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Chagas Disease (American Trypanosomiasis) Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific – Country wise Chagas Disease (American Trypanosomiasis) Clinical Trials and Enrolment
Figure 5: Europe – Country wise Chagas Disease (American Trypanosomiasis) Clinical Trials and Enrolment
Figure 6: Middle East Africa – Country wise Chagas Disease (American Trypanosomiasis) Clinical Trials and Enrolment
Figure 7: North America – Country wise Chagas Disease (American Trypanosomiasis) Clinical Trials and Enrolment
Figure 8: South and Central America – Country wise Chagas Disease (American Trypanosomiasis) Clinical Trials and Enrolment
Figure 9: Chagas Disease (American Trypanosomiasis) Clinical Trials by Phase
Figure 10: Chagas Disease (American Trypanosomiasis) Clinical Trials by Trial Status
Figure 11: Chagas Disease (American Trypanosomiasis) Clinical Trials by Type
Figure 12: Chagas Disease (American Trypanosomiasis) Clinical Trials by Sponsor Type
Figure 13: Chagas Disease (American Trypanosomiasis) Clinical Trials by Leading Sponsors
Figure 14: Chagas Disease (American Trypanosomiasis) Average Enrollment by Phase
Figure 15: Chagas Disease (American Trypanosomiasis) Average Enrollment by Trial Status
Figure 16: Chagas Disease (American Trypanosomiasis) Average Enrollment by Type
Figure 17: Chagas Disease (American Trypanosomiasis)- Average Enrolment by Type of Sponsors
Figure 18: Chagas Disease (American Trypanosomiasis)- Enrolment by Leading Sponsors
Figure 19: VPAResearch- Research Methodology

List of Tables
Table 1: Chagas Disease (American Trypanosomiasis) Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific – Country wise Chagas Disease (American Trypanosomiasis) Clinical Trials and Enrolment
Table 5: Europe – Country wise Chagas Disease (American Trypanosomiasis) Clinical Trials and Enrolment
Table 6: Middle East Africa – Country wise Chagas Disease (American Trypanosomiasis) Clinical Trials and Enrolment
Table 7: North America – Country wise Chagas Disease (American Trypanosomiasis) Clinical Trials and Enrolment
Table 8: South and Central America – Country wise Chagas Disease (American Trypanosomiasis) Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Chagas Disease (American Trypanosomiasis) Average Enrollment by Phase
Table 15: Chagas Disease (American Trypanosomiasis) Average Enrollment by Trial Status
Table 16: Chagas Disease (American Trypanosomiasis) Average Enrollment by Type
Table 17: Chagas Disease (American Trypanosomiasis)- Average Enrolment by Type of Sponsors
Table 18: Chagas Disease (American Trypanosomiasis)- Enrolment by Leading Sponsors

Companies mentioned
Bayer AG, Eisai Co Ltd, Humanigen Inc, Insud Pharma, Laboratory Corp of America Holdings, LAT Research, Leon Research SL, Merck & Co Inc, Pan American Health Organization, Sanofi